Compounded Bioidentical Hormone Therapy Market Size

  • Report ID: 4088
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Compounded Bioidentical Hormone Therapy Market size is expected to register around 5.2% CAGR during the forecast period i.e., between 2025-2037.

The compounded bioidentical hormone therapy utilizes processed hormones to help people in regulating the hormonal imbalances. It is estimated that around 80% women suffer from hormonal imbalance worldwide. The global compounded bioidentical hormone market is estimated to expand at a rapid rate over the forecast period on account of the increasing population of women with hormonal imbalances. Furthermore, compounded bioidentical hormone therapy can be used to treat conditions, such as, thyroid disorders, insulin resistance, osteoporosis, and fibromyalgia. As the number of patients is increasing worldwide, scientists are expeditiously researching the remedies, such as, bioidentical hormones. Additionally, menopause in women causes night sweats, insomnia, and hot flashes, which can be prevented by using compounded bioidentical hormone therapy. Owing to its various benefits, the global market is estimated to boost over the forecast period.



Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

The compounded bioidentical hormone therapy industry size is expected to register around 5.2% CAGR during the forecast period i.e., between 2025-2037.

The market growth is propelled by increasing health awareness amongst the people.

North America industry is expected to account for largest revenue share by 2037, on the back of higher healthcare expenditure, increasing thyroid prevalence amongst women, and more awareness amongst the people.

The major players in the market are Defy Medical, LLC, The biostation, Noven Pharmaceuticals, Inc., Novartis AG, and Pfizer Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos